Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.70 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 2/20 | 0.42 |
| ▸ | NQO2 | P16083 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261920 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BTP53POLB | |
| SCHEMBL5344278 | 0.81 | MTNR1A (0.72) | MTNR1ATRPV1ITGB3ITGA2BMTNR1B | |
| SCHEMBL5343316 | 0.80 | MTNR1A (0.56) | MTNR1ATRPV1ITGB3ITGA2BMALT1 | |
| SCHEMBL5334595 | 0.80 | MTNR1A (0.70) | MTNR1ATRPV1ITGB3ITGA2BMTNR1B | |
| SCHEMBL5346165 | 0.80 | MTNR1A (0.70) | MTNR1ATRPV1ITGB3ITGA2BMTNR1B | |
| SCHEMBL5346519 | 0.80 | MTNR1A (0.70) | MTNR1ATRPV1MALT1MTNR1BPOLB | |
| SCHEMBL6076652 | 0.80 | MTNR1A (0.70) | MTNR1ATRPV1ITGB3ITGA2BMALT1 | |
| SCHEMBL7822666 | 0.77 | MTNR1A (0.77) | MTNR1ATRPV1ITGB3ITGA2BMTNR1B | |
| SCHEMBL19658437 | 0.76 | MTNR1A (0.65) | MTNR1AMALT1MTNR1BTP53 | |
| SCHEMBL7027043 | 0.75 | MTNR1A (0.72) | MTNR1ATRPV1RORCTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | claimed |
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885TRPV1 2408/4885ITGB3 3090/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885TRPV1 2372/4885ITGB3 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.